Glaucoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 175 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Glaucoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Glaucoma - Pipeline Review, H2 2014', provides an overview of the Glaucoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Glaucoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Glaucoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Glaucoma Overview 9
Therapeutics Development 10
Pipeline Products for Glaucoma - Overview 10
Pipeline Products for Glaucoma - Comparative Analysis 11
Glaucoma - Therapeutics under Development by Companies 12
Glaucoma - Therapeutics under Investigation by Universities/Institutes 16
Glaucoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Glaucoma - Products under Development by Companies 21
Glaucoma - Products under Investigation by Universities/Institutes 24
Glaucoma - Companies Involved in Therapeutics Development 25
Allergan, Inc. 25
Advanced Cell Technology, Inc. 26
Merck & Co., Inc. 27
Santen Pharmaceutical Co., Ltd. 28
Novartis AG 29
Kowa Company, Ltd. 30
Merz Pharma GmbH & Co. KgaA 31
Teva Pharmaceutical Industries Limited 32
InSite Vision Incorporated 33
Can-Fite BioPharma Ltd. 34
NicOx S.A. 35
Acadia Pharmaceuticals Inc. 36
NeoStem, Inc. 37
Handok Inc. 38
AC Immune SA 39
Upsher-Smith Laboratories, Inc. 40
Foamix Ltd. 41
Senju Pharmaceutical Co., Ltd. 42
Neurotech Pharmaceuticals, Inc. 43
PharmaNova Inc. 44
Aerie Pharmaceuticals, Inc. 45
Lacer, S.A. 46
SIFI S.p.A 47
D. Western Therapeutics Institute, Inc. 48
Dompe Farmaceutici S.p.A. 49
DNAVEC Corporation 50
Altacor Ltd. 51
Ohr Pharmaceutical Inc. 52
Cancer Therapeutics CRC Pty Ltd 53
Mimetogen Pharmaceuticals Inc. 54
Icon Bioscience, Inc. 55
AUS Bio Limited 56
Ocular Therapeutix, Inc. 57
Clanotech AB 58
Bionure Farma, S.L. 59
SK Biopharmaceuticals Co., Ltd. 60
China Grand Wuhan General Pharmaceutical Research Institute 61
Glaucoma - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 68
Assessment by Route of Administration 71
Assessment by Molecule Type 74
Drug Profiles 76
ripasudil - Drug Profile 76
XY-1303LT2 - Drug Profile 77
XY-0811QF2 - Drug Profile 78
CF-101 - Drug Profile 79
bimatoprost SR - Drug Profile 82
latanoprost - Drug Profile 83
lomerizine - Drug Profile 85
SNJ-1656 - Drug Profile 86
travoprost SR - Drug Profile 87
(bimatoprost + brimonidine tartrate) - Drug Profile 88
(AR-13324 + latanoprost) - Drug Profile 89
NT-501 - Drug Profile 90
AC-262271 - Drug Profile 92
MRZ-99030 - Drug Profile 93
Recombinant Human Nerve Growth Factor - Drug Profile 94
SF-103 - Drug Profile 95
SF-108 - Drug Profile 96
SF-116 - Drug Profile 97
PRX-00933 - Drug Profile 98
MIMD-3 - Drug Profile 99
bimatoprost - Drug Profile 100
ACN-1052 - Drug Profile 101
LA-8045 - Drug Profile 102
ACI-260 - Drug Profile 103
Stem Cell Therapy for Macular Degeneration and Glaucoma - Drug Profile 104
MD-920G - Drug Profile 105
AP-022 - Drug Profile 106
BA-1049 - Drug Profile 107
AR-13533 - Drug Profile 108
NT-509 - Drug Profile 109
Small Molecules to Antagonize TRPM7 for Cardiovascular Disorders And Glaucoma - Drug Profile 110
minocycline Gel - Drug Profile 111
Stem Cell Therapy for Glaucoma - Drug Profile 112
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 113
PBF-695 - Drug Profile 114
Small Molecules to Inhibit LIMK1 AND LIMK2 for Cancer and Ophthalmology - Drug Profile 115
NCX-250 - Drug Profile 116
BN-201 - Drug Profile 117
latanoprost - Drug Profile 118
H-1129 - Drug Profile 119
KR-12 - Drug Profile 120
Small Molecule For Glaucoma - Drug Profile 121
NCX-1021 - Drug Profile 122
SKL-G - Drug Profile 123
Gene Therapy for Retinitis Pigmentosa and Glaucoma - Drug Profile 124
CLT-28643 - Drug Profile 125
ENV-515 - Drug Profile 126
APH-1104 - Drug Profile 127
Drugs for Steroid Induced Glaucoma - Drug Profile 128
SKS-1002 - Drug Profile 129
Small Molecules to Inhibit Rho Kinase for Glaucoma - Drug Profile 130
BA-240 - Drug Profile 131
TRV-32R - Drug Profile 132
SF-109 - Drug Profile 133
H-1129 Backup - Drug Profile 134
ALT-022 - Drug Profile 135
Recombinant Proteins to Activate EGFR for Metabolic Disorders and Ophthalmology - Drug Profile 136
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 137
Small Molecules to Activate sGC for Ophthalmology - Drug Profile 138
Drugs to Target Bestrophin-2 Gene for Glaucoma - Drug Profile 139
Gene Therapy for Ocular Diseases - Drug Profile 140
HL-3501 - Drug Profile 141
Drugs to Inhibit Cadherin-5 for Glaucoma - Drug Profile 142
Monoclonal Antibody to Activate Bves for Glaucoma - Drug Profile 143
(Prostaglandin Agonist + Beta-Blocker) - Drug Profile 144
CNS-102 - Drug Profile 145
Glaucoma - Recent Pipeline Updates 146
Glaucoma - Dormant Projects 155
Glaucoma - Discontinued Products 158
Glaucoma - Product Development Milestones 159
Featured News & Press Releases 159
Appendix 169
Methodology 169
Coverage 169
Secondary Research 169
Primary Research 169
Expert Panel Validation 169
Contact Us 170
Disclaimer 170

List of Tables
Number of Products under Development for Glaucoma, H2 2014 15
Number of Products under Development for Glaucoma - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Development by Companies, H2 2014 (Contd..1) 19
Number of Products under Development by Companies, H2 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Comparative Analysis by Unknown Stage Development, H2 2014 25
Products under Development by Companies, H2 2014 26
Products under Development by Companies, H2 2014 (Contd..1) 27
Products under Development by Companies, H2 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2014 29
Glaucoma - Pipeline by Allergan, Inc., H2 2014 30
Glaucoma - Pipeline by Advanced Cell Technology, Inc., H2 2014 31
Glaucoma - Pipeline by Merck & Co., Inc., H2 2014 32
Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 33
Glaucoma - Pipeline by Novartis AG, H2 2014 34
Glaucoma - Pipeline by Kowa Company, Ltd., H2 2014 35
Glaucoma - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2014 36
Glaucoma - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 37
Glaucoma - Pipeline by InSite Vision Incorporated, H2 2014 38
Glaucoma - Pipeline by Can-Fite BioPharma Ltd., H2 2014 39
Glaucoma - Pipeline by NicOx S.A., H2 2014 40
Glaucoma - Pipeline by Acadia Pharmaceuticals Inc., H2 2014 41
Glaucoma - Pipeline by NeoStem, Inc., H2 2014 42
Glaucoma - Pipeline by Handok Inc., H2 2014 43
Glaucoma - Pipeline by AC Immune SA, H2 2014 44
Glaucoma - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 45
Glaucoma - Pipeline by Foamix Ltd., H2 2014 46
Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2014 47
Glaucoma - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2014 48
Glaucoma - Pipeline by PharmaNova Inc., H2 2014 49
Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2014 50
Glaucoma - Pipeline by Lacer, S.A., H2 2014 51
Glaucoma - Pipeline by SIFI S.p.A, H2 2014 52
Glaucoma - Pipeline by D. Western Therapeutics Institute, Inc., H2 2014 53
Glaucoma - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 54
Glaucoma - Pipeline by DNAVEC Corporation, H2 2014 55
Glaucoma - Pipeline by Altacor Ltd., H2 2014 56
Glaucoma - Pipeline by Ohr Pharmaceutical Inc., H2 2014 57
Glaucoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 58
Glaucoma - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2014 59
Glaucoma - Pipeline by Icon Bioscience, Inc., H2 2014 60
Glaucoma - Pipeline by AUS Bio Limited, H2 2014 61
Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2014 62
Glaucoma - Pipeline by Clanotech AB, H2 2014 63
Glaucoma - Pipeline by Bionure Farma, S.L., H2 2014 64
Glaucoma - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 65
Glaucoma - Pipeline by China Grand Wuhan General Pharmaceutical Research Institute, H2 2014 66
Assessment by Monotherapy Products, H2 2014 67
Assessment by Combination Products, H2 2014 68
Number of Products by Stage and Target, H2 2014 71
Number of Products by Stage and Mechanism of Action, H2 2014 75
Number of Products by Stage and Route of Administration, H2 2014 78
Number of Products by Stage and Molecule Type, H2 2014 80
Glaucoma Therapeutics - Recent Pipeline Updates, H2 2014 151
Glaucoma - Dormant Projects, H2 2014 160
Glaucoma - Dormant Projects (Contd..1), H2 2014 161
Glaucoma - Dormant Projects (Contd..2), H2 2014 162
Glaucoma - Discontinued Products, H2 2014 163